Intercept Pharmaceuticals Inc (NASDAQ:ICPT) has been assigned a consensus recommendation of “Hold” from the twenty-five ratings firms that are currently covering the firm, Marketbeat.com reports. Five analysts have rated the stock with a sell rating, ten have given a hold rating and ten have given a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $127.06.

ICPT has been the subject of several recent research reports. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Oppenheimer reiterated a “hold” rating on shares of Intercept Pharmaceuticals in a report on Monday, January 29th. Citigroup set a $74.00 price target on Intercept Pharmaceuticals and gave the stock a “hold” rating in a report on Friday, December 29th. Bank of America decreased their price target on Intercept Pharmaceuticals from $102.00 to $73.00 and set an “underperform” rating for the company in a report on Friday, October 13th. Finally, Cowen reiterated a “buy” rating and set a $112.00 price target on shares of Intercept Pharmaceuticals in a report on Wednesday, November 1st.

Intercept Pharmaceuticals (NASDAQ ICPT) opened at $53.29 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 3.15. Intercept Pharmaceuticals has a 12-month low of $51.53 and a 12-month high of $135.59. The firm has a market capitalization of $1,457.93, a P/E ratio of -3.60 and a beta of -2.13.

Large investors have recently made changes to their positions in the business. WFG Advisors LP grew its stake in Intercept Pharmaceuticals by 16.4% in the 2nd quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 125 shares during the period. IFP Advisors Inc grew its stake in Intercept Pharmaceuticals by 90.9% in the 3rd quarter. IFP Advisors Inc now owns 2,482 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 1,182 shares during the period. PNC Financial Services Group Inc. grew its stake in Intercept Pharmaceuticals by 23.3% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,490 shares of the biopharmaceutical company’s stock valued at $302,000 after purchasing an additional 470 shares during the period. Nomura Holdings Inc. bought a new position in Intercept Pharmaceuticals in the 2nd quarter valued at $366,000. Finally, Cubist Systematic Strategies LLC grew its stake in Intercept Pharmaceuticals by 469.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 3,983 shares of the biopharmaceutical company’s stock valued at $482,000 after purchasing an additional 3,283 shares during the period. Hedge funds and other institutional investors own 74.37% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece was reported by Daily Political and is the property of of Daily Political. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dailypolitical.com/2018/02/09/intercept-pharmaceuticals-inc-icpt-receives-consensus-rating-of-hold-from-analysts.html.

About Intercept Pharmaceuticals

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Analyst Recommendations for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.